8-K: Tonix Pharmaceuticals Presents Promising Preclinical Data for Mpox Vaccine Candidate

Tonix Pharmaceuticals announced positive preclinical data for their mpox vaccine candidate, TNX-801, demonstrating tolerability and lack of spread in immunocompromised animals.

Summary

• Tonix Pharmaceuticals presented data on their mpox vaccine candidate, TNX-801, at the World Vaccine Congress-Europe 2024.
• The presentation highlighted positive preclinical efficacy data, showing that TNX-801 is well-tolerated in immunocompromised animals.
• TNX-801 did not spread in blood or tissues of these animals, even at doses approximately 100 times higher than traditional vaccinia vaccines.
• The vaccine is a single-dose, live, attenuated, minimally replicating vaccine based on synthesized horsepox.
• TNX-801 has previously shown to protect animals against lethal challenge with clade I monkeypox virus.
• The vaccine also reduced viral shedding in the mouth and lungs of animals challenged with clade I monkeypox.
• These findings suggest that TNX-801 induces mucosal immunity and has the potential to block forward transmission.
• The World Health Organization (WHO) has declared the recent outbreak of clade I mpox a Public Health Emergency of International Concern.
• The WHO's preferred target product profile for mpox vaccines aligns with the characteristics of TNX-801, including single-dose administration, durable protection, and stability at ambient temperature.
• Tonix has a collaboration with Bilthoven Biologics (Bbio) to develop GMP manufacturing processes for TNX-801.

Sentiment

Score: 8

Explanation: The document presents very positive preclinical data for a vaccine candidate addressing a significant public health concern. The alignment with WHO guidelines and the manufacturing collaboration further boost the positive sentiment.

Positives

• TNX-801 shows strong tolerability and efficacy profiles in preclinical studies.
• The vaccine is designed for single-dose administration, which is a significant advantage.
• TNX-801 has the potential to block forward transmission of mpox.
• The vaccine aligns with the WHO's preferred target product profile for mpox vaccines.
• The collaboration with Bbio for manufacturing enhances the potential for large-scale production.
• TNX-801 is based on a horsepox platform, which has shown promise in other vaccine development efforts.

Negatives

• The data presented is preclinical, and further clinical trials are needed to confirm the efficacy and safety in humans.
• The spread of clade I mpox is a growing concern, highlighting the urgency for effective vaccines.
• The company is still in the development phase and has not yet received regulatory approval for TNX-801.

Risks

• The development of TNX-801 is subject to the risks associated with pharmaceutical development, including clinical trial failures and regulatory hurdles.
• There is a risk that the vaccine may not be as effective in humans as it has been in preclinical studies.
• The company faces competition from other companies developing mpox vaccines.
• The company's ability to manufacture and distribute the vaccine at scale is dependent on the success of its collaboration with Bbio.
• The emergence of new mpox variants could potentially reduce the effectiveness of the vaccine.

Future Outlook

The company plans to continue the development of TNX-801 and move towards clinical trials. They are also working on manufacturing processes to ensure they can produce the vaccine at scale.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix, stated that data continue to support TNX-801's strong tolerability and efficacy profiles.
• He also mentioned that synthetic biology is an important technology for vaccine development as viral diseases continue to rapidly evolve.
• Management believes TNX-801 is in a strong position to make an impact towards preventing mpox and controlling mpox epidemics.

Industry Context

The announcement comes at a time when there is a growing concern about the spread of mpox, particularly the clade I strain. The development of a safe and effective vaccine is crucial for controlling the outbreak. The WHO has declared the mpox outbreak a public health emergency of international concern, highlighting the need for new vaccines.

Comparison to Industry Standards

• The document highlights that TNX-801 is designed to be a single-dose vaccine, which is a key advantage over some existing vaccines that require multiple doses.
• The vaccine's ability to not spread in immunocompromised animals, even at high doses, is a significant improvement over traditional vaccinia vaccines.
• The alignment of TNX-801 with the WHO's preferred target product profile suggests that it meets key criteria for an effective mpox vaccine.
• The collaboration with Bilthoven Biologics, part of the Cyrus Poonawalla Group, which includes the Serum Institute of India, provides access to significant manufacturing capacity, which is a key factor in the success of a vaccine.

Stakeholder Impact

• Shareholders may view the positive preclinical data as a positive development for the company.
• Employees may be motivated by the progress of the vaccine development.
• Customers (potential patients) may benefit from the development of a new mpox vaccine.
• Suppliers may see increased demand for materials related to vaccine production.
• Creditors may view the progress as a positive sign of the company's potential.

Next Steps

• The company will continue to develop TNX-801 and move towards clinical trials.
• Tonix will continue to work with Bilthoven Biologics to develop GMP manufacturing processes for the vaccine.

Key Dates

Keywords

Mpox, Vaccine, TNX-801, Horsepox, Preclinical, Immunocompromised, WHO, Bilthoven Biologics, Single-dose, Attenuated, Efficacy, Tolerability